BioCurex obtains patent for therapeutic application of RECAF marker
The Australian Patent Office has awarded BioCurex Inc. its first patent to develop applications of its proprietary RECAF technology to therapy. The approval is a sequel of the first approval to diagnostic application that was a part of the original filing. The company owns the technology to use RECAF, a molecule which is present inside and on the surface of cancer cells. These cells release some RECAF into the blood stream. This has led to the development of a blood test for cancer which can successfully diagnose about 90% of patients with malignancies with precision.
- Knee operation does not help osteoarthritis patients: Study
- ThromboVision commences clinical trials for T-Guide(R)
- FDA nod to Eisai’s ONTAK solution
- ReGear launches new heat therapy ReBound for treating pain
